All Articles
Analysis of the randomized COMBI-AD trial at 5 years shows >50% relapse-free survival in patients with resected stage III BRAF V600-mutation–positive melanoma who received adjuvant treatment with the combination of dabrafenib plus trametinib. Read More ›
In response to the COVID-19 pandemic, CMS has added coverage of telehealth services as part of a push by the agency to accelerate the use of telehealth by removing reimbursement barriers. Read More ›
The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum. Read More ›
In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation. Read More ›
A review of the National Cancer Database reveals that use of neoadjuvant chemotherapy for advanced epithelial ovarian cancer increased markedly between 2004 and 2016. At the same time, median survival improved by more than 6 months. Study authors found no association between the 2 trends. Read More ›
Data from a real-world setting show that a platinum-free interval >12 months was associated with the best outcomes after progression on PARP inhibitor maintenance in patients with high-grade serous ovarian cancer. Read More ›
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer. Read More ›
PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and BRCA1/2 mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and BRCA1 or BRCA2, and to a lesser extent ATM mutations, according to the final analysis of the phase 3 PROfound trial. Read More ›
On July 31, 2020, the FDA accelerated the approval of tafasitamab-cxix (Monjuvi; Incyte/MorphoSys US), a CD19-directed cytolytic antibody, in combination with lenalidomide (Revlimid) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem-cell transplant. Read More ›
On August 5, 2020, the FDA accelerated the approval of belantamab mafodotin-blmf (Blenrep; GlaxoSmithKline), a B-cell maturation antigen–directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received ≥4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Read More ›